These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Hyseq-Variagenics merger signals end of the line. Hodgson J Nat Biotechnol; 2003 Jan; 21(1):5. PubMed ID: 12511895 [No Abstract] [Full Text] [Related]
6. Biotech's new colossus. Move over, Big Pharma. Amgen boasts better growth. Stipp D Fortune; 2002 Apr; 145(8):144-6, 148, 150. PubMed ID: 11961884 [No Abstract] [Full Text] [Related]
7. For success, focus your strengths. Levinson AD Nat Biotechnol; 1998 May; 16 Suppl():45-6. PubMed ID: 9591268 [No Abstract] [Full Text] [Related]
8. From scandal to stardom: how Merck healed itself. Simons J Fortune; 2008 Feb; 157(3):94-6, 98. PubMed ID: 18335777 [No Abstract] [Full Text] [Related]
9. Advice for partnering with pharma. Howard K Nat Biotechnol; 2004 Nov; 22(11):1477-9. PubMed ID: 15586421 [No Abstract] [Full Text] [Related]
10. Row over industry link-up splits staff of Spanish lab. Fernandez Hermana LA Nature; 1994 Dec; 372(6507):586. PubMed ID: 7990935 [No Abstract] [Full Text] [Related]
11. The science-business tango. Interview by Mari Paul. Hirth P Nat Biotechnol; 2006 Aug; 24(8):1035-6. PubMed ID: 16900153 [No Abstract] [Full Text] [Related]
12. Merck's man in the hot seat. Simons J Fortune; 2004 Feb; 149(4):111-2, 114. PubMed ID: 14983668 [No Abstract] [Full Text] [Related]
13. The executive's role in ethics: the view from business and industry. Rossy GL Healthc Exec; 1987; 2(5):18-21. PubMed ID: 10302068 [No Abstract] [Full Text] [Related]